• LOGIN
    Login with username and password
Repository logo

BORIS Portal

Bern Open Repository and Information System

  • Publications
  • Theses
  • Research Data
  • Projects
  • Organizations
  • Researchers
  • More
  • Collections
  • Statistics
  • LOGIN
    Login with username and password
Repository logo
Unibern.ch
  1. Home
  2. Publications
  3. Therapeutic Potential of Chimeric Antigen Receptor-Expressing Mesenchymal Stem Cells in the Treatment of Inflammatory and Autoimmune Diseases.

Therapeutic Potential of Chimeric Antigen Receptor-Expressing Mesenchymal Stem Cells in the Treatment of Inflammatory and Autoimmune Diseases.

Details
Files
DOI
10.48620/91183
Publisher DOI
10.3390/ijms26167795
PubMed ID
40869115
Abstract
Chimeric antigen receptor-engineered mesenchymal stem cells (CAR-MSCs) represent a novel and highly adaptable platform for the targeted treatment of inflammatory and autoimmune diseases. By integrating the inflammation-homing and immunomodulatory properties of mesenchymal stem cells (MSCs) with the antigen-specific recognition and activation potential of chimeric antigen receptors (CARs), CAR-MSCs enable site-specific delivery of therapeutic agents directly to inflamed or diseased tissues. This dual functionality enhances therapeutic precision while minimizing off-target effects and systemic toxicity. Recent preclinical studies have demonstrated the efficacy of CAR-MSCs in modulating pathogenic immune responses, reducing local inflammation, and promoting tissue repair in various disease models. CAR-MSCs have been engineered to recognize and interact with disease-specific antigens or inflammatory markers, allowing them to selectively suppress the activation and proliferation of autoreactive immune cells. This targeted immunosuppression offers a promising strategy for restoring immune tolerance without the risks associated with systemic immunosuppression. In this review, we provide a comprehensive overview of recent developments in CAR-MSC design, highlight mechanisms by which CARs enhance MSC functionality, and discuss key challenges, including safety, scalability, and regulatory considerations. Collectively, these emerging approaches hold substantial promise for reshaping future therapies for inflammatory and autoimmune diseases.
Date Issued
2025-08-12
Publication Type
Article
Subject(s)
600 Technology > 610 Medicine & health
Subjects
autoimmune diseases
•
cell-based therapy
•
chimeric antigen receptor
•
inflammatory diseases
•
mesenchymal stem cells
Language(s)
en
Author(s)
Volarevic, Vladislav  
Harrell, Carl Randall
Fellabaum, Crissy
Djonov, Valentin  orcid-logo
Institute of Anatomy, Topographical and Clinical Anatomy  
Institute of Anatomy  
Volarevic, Ana
Additional Credits
Institute of Anatomy, Topographical and Clinical Anatomy  
Institute of Anatomy  
Journal
International Journal of Molecular Sciences
Publisher
MDPI
ISSN
1422-0067
1661-6596
Access(Rights)
open.access
Show full item
BORIS Portal
Bern Open Repository and Information System
Build: 24f0a9 [ 4.09. 8:55]
Explore
  • Projects
  • Funding
  • Publications
  • Research Data
  • Organizations
  • Researchers
  • Audiovisual Material
  • Software & other digital items
  • Events
More
  • About BORIS Portal
  • BORIS Portal & Open Science
  • Send Feedback
  • Cookie settings
  • Service Policy
Follow us on
  • Mastodon
  • YouTube
  • LinkedIn
UniBe logo
Repository logo COAR Notify